The California Institute for Regenerative Medicine (CIRM) approved a $100 million Rare Disease Acceleration Platform and Innovation and Delivery (RAPID) program to fund platform approaches that aim to deliver in‑vivo genetic therapies across multiple rare indications. The initiative focuses on scalable manufacturing and regulatory strategies to move beyond single‑disease, one‑off development models. CIRM said RAPID will support projects with FDA engagement and pre‑IND feedback, funding activities from IND‑enabling studies through first‑in‑human trials. The program aims to replicate recent personalized successes—such as a bespoke CRISPR therapy—on a platform scale and reduce time and cost to clinic for rare genetic disorders.